Why is Glenmark Pharma falling/rising?

As of 05-Aug, Glenmark Pharmaceuticals Ltd. is currently priced at 2,049.00, reflecting a decline of 25.05 points or 1.21%. The stock has underperformed its sector by 0.26% today, and its delivery volume has decreased significantly, falling by 34.7% compared to the 5-day average. Over the past week, the stock has experienced a decline of 5.12%, although it has shown strong performance over the longer term, with a 44.73% increase over the past year. The company has demonstrated a robust ability to service its debt, evidenced by a low Debt to EBITDA ratio of 1.00 times, and has reported positive results for the last four consecutive quarters, with a remarkable growth in PAT of 576.7% compared to the previous four-quarter average. Additionally, the stock is trading at a discount relative to its peers, supported by high institutional holdings at 38.3%, indicating confidence from more informed investors.
In the broader market context, Glenmark's short-term performance has been notably weaker than the benchmark, with a 1-week return of -5.12% compared to the Sensex's -0.77%. Despite this recent downturn, the stock has outperformed the BSE500 over the last three years, generating consistent returns. The company's strong fundamentals, including a return on equity of 14.1 and a favorable PEG ratio of 0.2, suggest that while the stock is facing short-term challenges, it has the potential for recovery and growth in the long run.